Bob Blouin speaks during the Pinnacle Hill announcement event.

Pinnacle Hill, UNC-Chapel Hill’s new partnership with Deerfield Management, offers faculty at the UNC Eshelman School of Pharmacy an opportunity to pursue funding to advance novel drug therapy projects. All UNC investigators are encouraged to submit therapeutic preproposals to Pinnacle Hill for potential funding, which may support studies to reach the IND-ready stage.

Mark your calendar for these important dates:

  • Monday, Jan. 7: Preproposal RFP opens
  • Wednesday, Feb. 6: Preproposal RFP closes

Which therapeutic areas will the RFP cover?

This RFP is directed toward any and all therapeutic areas that address unmet medical needs. It includes any type of drug treatment: small molecules, gene therapies, antibodies, proteins, peptides, exosomes, cells and other modalities. All delivery methods will be considered.

What types of proposals will Pinnacle Hill look for?

Pinnacle Hill seeks proposals for transformational approaches based on existing or new intellectual property that it can develop to IND-ready status. Therefore, a clear path to IND will be especially interesting to reviewers.

What’s the process?
After thorough review of all preproposals, Pinnacle Hill will invite selected investigators to submit full proposals in spring 2019. Projects that successfully reach the IND-ready stage will be licensed to a new startup company or to a commercial development partner. Projects that are not successful will be returned to UNC-Chapel Hill with all data and IP generated by Pinnacle Hill for further development by the University and its investigators.

Visit the Pinnacle Hill website to find more information about the RFP process, an FAQ and key dates.

Comments are closed.